An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This study uses polysomnographs(PSG) to investigate sleep patterns in patients with bipolar
depression. This is a double-blind, placebo-controlled, study of ziprasidone that is added to
patients current medications. The objective is to relate changes in slow wave and rapid eye
movement sleep to changes in mood and overall illness severity. Participants will be randomly
assigned to add either placebo or ziprasidone to their current treatment regimen.
Participants make 3 to 4 study visits, over a 1 month period, at which they will be asked
about their history, mood and sleep quality. Participants will also have three in-home
overnight polysomnographs.
Phase:
Phase 4
Details
Lead Sponsor:
Queen's University
Collaborators:
MDS Pharma Services Pfizer Providence Health & Services